Biogen (NASDAQ: BIIB) legal chief exercises RSUs, withholds stock for taxes

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Biogen Inc. executive Susan H. Alexander, EVP Chief Legal Officer, reported multiple equity transactions on 02/06/2026. Several restricted stock unit awards were exercised, delivering 2,190, 1,940 and 4,916 shares of Biogen common stock at an exercise price of $0.

In related transactions, 1,059, 931 and 1,514 shares of common stock were withheld at a price of $201.18 per share, typically reflecting shares retained to cover tax obligations. After these transactions, she directly held 41,807 shares of Biogen common stock and indirectly held 20,082 shares through the Susan H. Alexander 2021 Irrevocable Trust.

Insider Trade Summary

9,046 shares exercised/converted

Mixed 10 txns

Insider ALEXANDER SUSAN H

Role EVP Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	2,190	$0.00	--
Exercise	Restricted Stock Unit	1,940	$0.00	--
Exercise	Restricted Stock Unit	4,916	$0.00	--
Exercise	Common Stock	2,190	$0.00	--
Tax Withholding	Common Stock	1,059	$201.18	$213K
Exercise	Common Stock	1,940	$0.00	--
Tax Withholding	Common Stock	931	$201.18	$187K
Exercise	Common Stock	4,916	$0.00	--
Tax Withholding	Common Stock	1,514	$201.18	$305K
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 38,455 shares (Direct); Common Stock — 20,082 shares (Indirect, Susan H. Alexander 2021 Irrevocable Trust)

Footnotes (1)

The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 2/8/2023. The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.

Form 4 Insider Transactions: What Each Field Means →

02/10/2026 - 04:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALEXANDER SUSAN H

(Last)

(First)

(Middle)

BIOGEN INC.

225 BINNEY STREET

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/06/2026		M		2,190	A	$0	38,455	D
Common Stock	02/06/2026		F		1,059	D	$201.18	37,396	D
Common Stock	02/06/2026		M		1,940	A	$0	39,336	D
Common Stock	02/06/2026		F		931	D	$201.18	38,405	D
Common Stock	02/06/2026		M		4,916	A	$0	43,321	D
Common Stock	02/06/2026		F		1,514	D	$201.18	41,807	D
Common Stock								20,082	I	Susan H. Alexander 2021 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	$0	02/06/2026		M			2,190	⁽¹⁾	02/08/2026	Common Stock	2,190	$0	0	D
Restricted Stock Unit	$0	02/06/2026		M			1,940	⁽²⁾	02/07/2027	Common Stock	1,940	$0	1,940	D
Restricted Stock Unit	$0	02/06/2026		M			4,916	⁽³⁾	02/06/2028	Common Stock	4,916	$0	9,834	D

Explanation of Responses:

1. The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 2/8/2023.

2. The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.

3. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.

	/s/ Wendell Taylor, attorney-in-fact for Susan Alexander	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Biogen (BIIB) report for Susan H. Alexander on February 6, 2026?

Biogen reported that EVP Chief Legal Officer Susan H. Alexander exercised restricted stock units into 2,190, 1,940 and 4,916 common shares, and had 1,059, 931 and 1,514 shares withheld at $201.18 per share, typically to satisfy tax obligations tied to those equity awards.

How many Biogen (BIIB) shares does Susan H. Alexander hold after the February 2026 Form 4?

After the reported transactions, Susan H. Alexander directly held 41,807 Biogen common shares. She also indirectly held 20,082 additional shares through the Susan H. Alexander 2021 Irrevocable Trust, reflecting both her personal and trust-related beneficial ownership positions disclosed in the filing.

What types of equity awards were involved in the February 6, 2026 Biogen (BIIB) insider filing?

The filing shows restricted stock units converting into Biogen common stock. RSU tranches of 2,190, 1,940 and 4,916 units were exercised at $0, consistent with vesting of stock-based compensation granted in 2023, 2024 and 2025 under the company’s equity incentive arrangements.

Why were some Biogen (BIIB) shares reported as disposed of at $201.18 on February 6, 2026?

Shares marked with code “F” indicate shares withheld to cover taxes from RSU vesting. On February 6, 2026, 1,059, 931 and 1,514 Biogen common shares were withheld at $201.18 per share in connection with the RSU conversions reported for Susan H. Alexander.

What do the vesting schedules in the Biogen (BIIB) Form 4 footnotes indicate?

The footnotes state that the restricted stock units vest in three equal annual installments. The tranches reported relate to grants dated February 8, 2023, February 7, 2024 and February 6, 2025, each beginning to vest one year after the respective grant date according to the disclosed schedules.